Recombinant Human MICA His-tag Protein, CF

When Recombinant Human NKG2D Fc Chimera (Catalog # 1299-NK) is immobilized at 1.0 μg/mL, 100 μL/well, the concentration of Recombinant MICA His-tag (Catalog # 10153-MA) that produces 50% of the optimal binding response is approximately 0.1-0.5 μg/mL.

2 μg/lane of Recombinant Human MICA His-tag(Catalog # 10153-MA) was resolved with SDS-PAGE under reducing (R) andnon-reducing (NR) conditions and visualized by Coomassie®Blue staining, showing bands at 50-70 kDa.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human MICA His-tag Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human NKG2D/CD314 Fc Chimera (Catalog # 1299-NK) is immobilized at 1.0 μg/mL, 100 μL/well, the concentration of Recombinant Human MICA His-tag (Catalog # 10153-MA) that produces 50% of the optimal binding response is 0.1-0.5 μg/mL.
  
• Source: Chinese Hamster Ovary cell line, CHO-derived human MICA protein
  Ala23-Gln308, with a C-terminal 6-His tag
• Accession #: Q29983
• N-terminal Sequence: Ala23
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 34 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 50-70 kDa, under reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in MOPS, NaCL with trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 250 μg/mL in sterile water

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human MICA His-tag Protein, CF

• FLJ60820
• MGC111087
• MICA
• PERB11.1

Background

Major Histocompatibility Complex Class I Chain-related Gene A (MICA) is a transmembrane glycoprotein that functions as a ligand for human Natural-Killer Group 2 Member D (NKG2D) (1). MICA, along with MICB, which shares 91% sequence identity (2), are members of the non-classical MHC class I family. The domain structure of MICA is similar to classical MHC class I proteins: three extracellular Ig-like domains ( alpha 1, alpha 2, and alpha 3) in the extracellular domain (ECD), a transmembrane segment, and a carboxy-terminal cytoplasmic tail (2). Despite structural similarities, MICA shares only 27% amino acid (aa) identity with human MHC class I proteins (3). Both MICA and MICB display a significant degree of polymorphism within the ECD and these allow MICA to be reconfigured and bind with NKG2D rather than binding with beta 2-microglobulin (4, 5). MICA genes occur in most mammalian species, but are absent from mouse and rat (2, 4). The genes encoding MICA and MICB are found within the MHC on the short arm of human chromosome 6 (2, 3). MICA is a ligand for human NKG2D, an activating receptor expressed on NK cells, NKT cells, gamma δ T cells, and CD8+ alpha beta T cells (6). Recognition of MICA by NKG2D results in the activation of cytolytic activity and/or cytokine production by these effector cells (4, 7). MICA recognition is involved in tumor surveillance, viral infections, and autoimmune diseases (8).

1. Huang, C. et al. (2018) Sci. Rep. 8:15821.
2. Bahram, S. et al. (1994) Proc. Natl. Acad. Sci. USA 91:6259.
3. Cosman, D. et al. (2001) Immunity 14:123.
4. Stephens, H. A. F. et al. (2001) Trends in Immunology 22:378.
5. Groh, V. et al. (1996) Proc. Natl. Acad. Sci. USA 93:12445.
6. Bauer, S. et al. (1999) Science 285:727.
7. Kawabata, Y. et al. (2000). Human Immunology. 61: 624.
8. Bahram, S. et al. (1994) Proc. Natl. Acad. Sci. USA 91:6259.

Bioinformatics

• Uniprot:
  • Q29983()